AbCellera Biologics Inc.
ABCL
$2.35
-$0.04-1.67%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -22.39% | -11.14% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -22.39% | -11.14% | |||
| Cost of Revenue | 12.47% | 0.10% | |||
| Gross Profit | -19.05% | -2.55% | |||
| SG&A Expenses | -13.99% | -4.48% | |||
| Depreciation & Amortization | -152.64% | 1.09% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -54.27% | -0.60% | |||
| Operating Income | 56.49% | -0.22% | |||
| Income Before Tax | 25.23% | -29.98% | |||
| Income Tax Expenses | -9.49% | -2.38% | |||
| Earnings from Continuing Operations | 33.06% | -38.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.06% | -38.39% | |||
| EBIT | 56.49% | -0.22% | |||
| EBITDA | 54.10% | 0.33% | |||
| EPS Basic | 33.18% | -38.09% | |||
| Normalized Basic EPS | 61.36% | -72.35% | |||
| EPS Diluted | 33.18% | -33.31% | |||
| Normalized Diluted EPS | 61.36% | -72.35% | |||
| Average Basic Shares Outstanding | 0.23% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.23% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
